Selective inhibitors of biogenic amine transporters

US5747503A · kind A · utility

Assignees

• The United States of America, as represented by the Department of Health and Human Services · US
• Research Triangle Institute · US

Inventors

• Richard B. Rothman · Baltimore, US
• Frank Ivy Carroll · Durham, US
• Bruce E. Blough · Raleigh, US
• Samuel W. Mascarella · Hillsborough, US

Key dates

• Filing date: Nov 12, 1996
• Grant date: May 5, 1998
• Expiry date: Nov 12, 2016

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D451/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2, N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3, and (CH.sub.2).sub.n, if present, may be substituted with OH, OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease.